1. An inhibitor of collagenase of apparent mol.wt. 28 000 was isolated from term human amniotic fluid. 2. It is active against mammalian collagenases from a number of species and tissues as well as other mammalian metalloproteinases, but has no activity against bacterial metalloproteinases. 3. Activity is destroyed by treatment with either trypsin or 4-aminophenylmercuric acetate, by heat, and by reduction and carboxymethylation. 4. All the properties observed suggest that it is similar to the synthesized tissue inhibitor of metalloproteinases.
It has been proposed that all connective tissues synthesize collagenase inhibitors to control the local activity of the enzyme (Reynolds et al., 1977; Murphy & Sellers, 1980) . Workers in a number of other laboratories have also described such inhibitors in tissue-culture media (Vater et al., 1978; Welgus et al., 1979; Kerwar et al., 1980) . Further to this, Sellers et al. (1979) have shown that the bone-derived collagenase inhibitors inhibit other metalloproteinases produced by connective tissues in culture. Collagenase inhibitors from human and dog serum have been isolated and characterized by Woolley et al. (1976 Woolley et al. ( , 1978 but the relationship between these and the tissue-synthesized inhibitors is not yet known. In the present paper we report the presence of a collagenase inhibitor in human amniotic fluid, and on the basis of its behaviour during purification and its subsequent characterization, we compare it with the purified inhibitor ('TIMP') synthesized by rabbit bones in culture and described in the preceding paper (Cawston et al., 1981) .
Materials and methods

Materials
All chemicals and biochemicals were described in the preceding paper (Cawston et al., 1981) .
Methods
Inhibitor purification. This was performed by the Abbreviation used: SDS, sodium dodecyl sulphate.
method of Cawston et al. (1981) , with crude rabbit skin collagenase activated by treatment with 4-aminophenylmercuric acetate (Sellers et al., 1978) as a monitor of inhibitory activity. The subsequent 1251I labelling with Bolton & Hunter reagent and SDS/ polyacrylamide-gel-electrophoresis techniques were described in the preceding paper (Cawston et al., 1981) . Assays. Collagenase and gelatinase assays were performed as described previously (Sellers et al., 1978 (Sellers et al., , 1979 . For comparative purposes the diffusefibril assay for collagenase (Cawston & Barrett, 1979) was also used for the final assessment of the purified inhibitor activity ( Cawston et al. (1981) . Inhibitor activity was assessed either by inclusion with the enzyme in the assay for 15-20h incubations, or by 1 h preincubation at 370C with the enzyme in 1-2h assays.
Sources of enzyme. Purified rabbit bone collagenase and pig synovial collagenase were prepared by the method of Cawston & Tyler (1979) , with the respective culture media as starting material. Rabbit skin and human rheumatoid-synovial collagenase were peaks of activity from the fractionation of culture media with Ultrogel AcA44 (Sellers et al., 1978) , as were the tissue gelatinases and metalloproteinase III (caseinase). Human leucocyte collagenase and gelatinase were prepared by using the protocol described by Cawston & Tyler (1979) . All Table 1 . Purification ofan inhibitor ofcollagenasefrom human amnioticfluid
The purification was performed as described under 'Methods' and by Cawston et al. (1981) . Inhibitory activity was monitored by using rabbit skin collagenase in the conventional fibril-assay system. Values in parentheses are those obtained by using the diffuse-fibril assay (see 'Methods'). Table 3 below; the inhibitor was exhaustively dialysed against the above buffer before assay. Heat treatment was performed at the same concentration and in the same buffer as described for trypsin treatment.
Results
The purification of the collagenase-inhibitory activity of amniotic fluid could be effected by using the protocol for the rabbit bone collagenase inhibitor derived from tissue culture, as described by Cawston et al. (1981) (present Table 1 ). Most of the activity bound to concanavalin A-Sepharose and was eluted with 5% (w/v) a-D-methyl mannoside, indicating that it is a glycoprotein. Subsequent purification on heparin-Sepharose, DEAESepharose and Zn2+-iminodiacetic acid-Sepharose gave a preparation of specific activity 19000units/ mg of protein. This compares with a value of 26 000 units/mg for the rabbit bone inhibitor. The inhibitor was labelled with 125I by using the Bolton & Hunter reagent and subjected to SDS/polyacrylamide-gel electrophoresis (Fig. 1) . It ran as a single band of apparent mol.wt. 28 000, as did the rabbit bone inhibitor. On Ultrogel AcA 44 filtration the amnioticfluid inhibitor was eluted as a single peak corresponding to an apparent mol.wt. of 33 000.
Between 10 and 40% of the original amniotic-fluid inhibitory activity (after the first-gel filtration step; described under 'Methods'. The activities of the purified major inhibitor on different preparations of collagenase are given in Table 2 . It appeared to act most efficiently against rabbit or pig tissue enzymes and was less active against the human synovial collagenase preparation available. It is possible that this reflects the amount of catalytically inactive collagenase in human tissue-culture media. The amniotic-fluid inhibitor acted only weakly against human leucocyte collagenase, in a manner analogous to both the rabbit bone inhibitor and fl,-anticollagenase (Woolley et al., 1978) .
The fully purified amniotic-fluid inhibitor was active against other mammalian metalloproteinases, as shown in Table 2 . However, it had no activity against either bacterial collagenase (with collagen as substrate) or thermolysin (either gelatin or casein as substrates). It also had no activity against serine proteinases such as plasmin and trypsin. Table 3 shows the destructive effect of both trypsin and 4-aminophenylmercuric acetate treatment on the purified inhibitor. Reduction and alkylation also removed the inhibitory activity. The inhibitor was relatively heat-stable, activity being destroyed after 30min at 900 C.
Discussion
The presence of collagenase inhibitors in connective tissues has been described by workers in a number of laboratories (Reynolds et al., 1977; Nolan et al., 1978; Woolley et al., 1978; Roughley et al., 1978; Vater et al., 1979; Welgus et al., 1979) , indicating that mechanisms for the control of extracellular enzyme activity are an important feature in determining rates of collagen degradation. Of most apparent significance are the inhibitors produced by connective tissues in culture (Reynolds et al., 1977) , although these inhibitors do not appear to be related to those extracted from tissue (Roughley et al., 1978) . The finding that amniotic fluid contains a collagenase inhibitor with similar size and charge, i.e. similar behaviour on purification, to a synthesized inhibitor from rabbit bone cultures suggests that there is a relationship between inhibitors produced in vitro and those found in vivo. Further studies are required to characterize both inhibitors more fully, in terms of their interaction with collagenase and other metalloproteinases. We have also found that rabbit amniotic fluid, human cerebrospinal fluid and human synovial fluid contain collagenase inhibitors. Although the precise role of these inhibitors is uncertain, their occurrence in vivo suggests that they play a part in the regulation of metalloproteinase activity. It is likely that the second inhibitor found in human amniotic fluid, which did not bind to concanavalin A-Sepharose, was the same as the binding activity, but had lost Table 3 . Effect ofvarious treatments on the activity ofhuman amniotic-fluid inhibitor ofcollagenase The effect of trypsin, 4-aminophenylmercuric acetate, reduction and alkylation, and heat, on the activity of the final preparations of purified concanavalin A-binding inhibitor were studied as described under 'Methods'. The results are expressed as percentage inactivations relative to inhibitor held under the same incubation conditions (A, B, C) or untreated material (D). 
